• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D filed by Smith & Nephew SNATS Inc.

    7/9/24 12:00:10 PM ET
    $SNN
    Industrial Specialties
    Health Care
    Get the next $SNN alert in real time by email
    SC 13D 1 p24-2324sc13d.htm SMITH & NEPHEW PLC

     

    SECURITIES AND EXCHANGE COMMISSION  
    Washington, D.C. 20549  
       
    SCHEDULE 13D
     
    Under the Securities Exchange Act of 1934*
     
     

    Smith & Nephew plc

    (Name of Issuer)
     

    Ordinary Shares of 20¢ each

    (Title of Class of Securities)
     

    83175M205**

    (CUSIP Number)
     

    Cevian Capital II GP Limited

    Whiteley Chambers

    Don Street

    St. Helier, Jersey JE2 4TR

    Channel Islands

    Attention: Norma O’Sullivan

    +44 1534 828 514

     

    with a copy to:

     

    Schulte Roth & Zabel LLP

    919 Third Avenue

    New York, NY 10022

    Attention:

    Adriana F. Schwartz, Esq.

    Eleazer N. Klein, Esq.

    (212) 756-2000

     

    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)
     

    July 2, 2024

    (Date of Event Which Requires Filing of This Statement)
     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the following box. [ ]

     (Page 1 of 8 Pages)

    ______________________________

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    ** The Ordinary Shares have no CUSIP number. CUSIP number 83175M205 has been assigned to the American Depositary Shares (“ADSs”) of the Issuer. Each ADS represents two Ordinary Shares. The ISIN number for the Ordinary Shares is GB0009223206.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     
     

     

    1

    NAME OF REPORTING PERSON

    Cevian Capital II GP Limited

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS

    AF

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Jersey

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    7

    SOLE VOTING POWER

    44,666,263

    8

    SHARED VOTING POWER

    0

    9

    SOLE DISPOSITIVE POWER

    44,666,263

    10

    SHARED DISPOSITIVE POWER

    0

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

    44,666,263

    12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    5.11%

    14

    TYPE OF REPORTING PERSON

    IA, OO

             

     

     

     

     
     

     

    Item 1. SECURITY AND ISSUER
       
      This statement on Schedule 13D (the “Schedule 13D”) relates to the Ordinary Shares of 20¢ each (the “Ordinary Shares”) of Smith & Nephew plc, a public limited company incorporated under the laws of England and Wales (the “Issuer”). The principal executive offices of the Issuer are located at Building 5, Croxley Park Hatters Lane, Watford Hertfordshire WD18 8YE United Kingdom.

     

    Item 2. IDENTITY AND BACKGROUND
       
    (a) This Schedule 13D is filed by Cevian Capital II GP Limited, a limited company incorporated under the laws of Jersey (the “Reporting Person”), the general partner of Cevian Capital II Master Fund L.P., a Cayman Islands limited partnership (the “Master Fund”), with respect to the Ordinary Shares held by the Master Fund.  
       
      The filing of this statement should not be construed as an admission that the Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, as amended, the beneficial owner of the Ordinary Shares reported herein.
       
    (b) The principal business address of the Reporting Person is Capital House, 8 Church Street, St. Helier, Jersey, JE2 3NN, Channel Islands.
       
    (c) The principal business of the Reporting Person is to serve as the sole general partner and to act as investment manager to the Master Fund.
       
    (d) The Reporting Person has not, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
       
    (e) The Reporting Person has not, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and, as a result of such proceeding, was, or is subject to, a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
       
    (f) The Reporting Person is a limited company organized under the laws of Jersey.
       
      Schedule A attached hereto sets forth the information required by Instruction C of the instructions to Schedule 13D.  

      

    Item 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION
       
      As of the date hereof, the Reporting Person has purchased for the account of the Master Fund an aggregate of 44,666,263 Ordinary Shares for an aggregate consideration (including brokerage commission) of approximately USD $561,244,640.  The Master Fund funded these purchases out of its general working capital. The Ordinary Shares were purchased using British Pounds. For the purposes of this Schedule 13D, a conversion rate of USD $1.27615 for each GBP 1.00 was used.

     

    Item 4. PURPOSE OF TRANSACTION
       
      The Reporting Person acquired the Ordinary Shares to which this Schedule 13D relates for investment purposes in the ordinary course of business because it believed the Ordinary Shares represented an attractive investment opportunity.
       

      In pursuing its investment purposes, the Reporting Person may further purchase, hold, vote, trade, dispose, engage in hedging or in similar transactions with respect to the Ordinary Shares, ADSs or other securities of the Issuer or securities related thereto at times, and in such manner, as it deems advisable to benefit from or on account of various factors, including but not limited to changes in market prices of such securities, changes in the Issuer’s operations, business strategy or prospects, acquisitions or the sale (or other disposition) or merger of the Issuer or any part of the Issuer’s business, or similar transactions. To evaluate such alternatives, the Reporting Person will routinely monitor, among other things, the Issuer’s operations, organizational and reporting structure, prospects, business development, performance of business units, governance, management, executive compensation, development of competitive positions, strategic matters and transactions (including acquisitions or the sale (or other disposition) or merger of the Issuer or any part of the Issuer’s business, or similar transactions), capital structure, and prevailing market conditions, as well as alternative investment opportunities, liquidity requirements of the Reporting Person and other investment considerations. Consistent with its investment research methods and evaluation criteria, the Reporting Person has discussed and intends to continue to discuss such matters with management, senior executives or the Board of the Issuer, other shareholders or investors, industry analysts, existing or potential strategic partners, acquirers or competitors, investment and financing professionals and other advisors, sources of credit and other relevant third parties. Such factors and discussions may materially affect, and result in, the Reporting Person modifying the Master Fund’s ownership of the Ordinary Shares, ADSs or other securities of the Issuer or securities related thereto, exchanging information with the Issuer and any of the foregoing persons pursuant to appropriate confidentiality or similar agreements (which may contain customary standstill provisions), proposing changes in the Issuer’s operations, governance, management, listing, capitalization, use of capital, financial metrics, capital allocations, organizational and reporting structure, corporate structure, strategy and plans of the Issuer (including acquisitions or the sale (or other disposition) or merger of the Issuer or any part of the Issuer’s business, or similar transactions), executive compensation, proposing or nominating director candidates to the Issuer’s board of directors, changing their intention with respect to any and all matters referred to in Item 4 of Schedule 13D and/or in proposing one or more of the other actions described in subsections (a) through (j) of Item 4 of Schedule 13D as the Reporting Person may deem appropriate. The Reporting Person may also take steps to explore and prepare for various plans and actions, and propose transactions, before forming an intention to engage in such plans or actions or proceed with such transactions.
       
      Except as set forth herein, the Reporting Person has no present plan or proposal that would relate to or result in any of the matters set forth in subparagraphs (a)-(j) of Item 4 of Schedule 13D.

     

    Item 5. INTEREST IN SECURITIES OF THE ISSUER
       
    (a) See rows (11) and (13) of the cover page to this Schedule 13D for the aggregate number of Ordinary Shares and percentages of the Ordinary Shares beneficially owned by the Reporting Person.  The percentage reported in this Schedule 13D is calculated based upon 874,350,233 Ordinary Shares reported to be outstanding as of June 30, 2024 in the Issuer’s Report of Foreign Private Issuer on Form 6-K filed with the Securities and Exchange Commission (“SEC”) on July 1, 2024.
       
    (b) See rows (7) through (10) of the cover page to this Schedule 13D for the number of Ordinary Shares as to which the Reporting Person has the sole power to vote or direct the vote and sole power to dispose or to direct the disposition.
       
    (c) The transactions in the Ordinary Shares by the Reporting Person for the benefit of the Master Fund within the past sixty days are set forth in Schedule B, and are incorporated herein by reference.  
       
    (d) No person other than the Master Fund and the Reporting Person is known to have the right to receive, or the power to direct the receipt of dividends from, or proceeds from the sale of, such Ordinary Shares.
       
    (e) Not applicable.
       

     

    Item 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER
       

      To the best of the Reporting Person’s knowledge, there are no contracts, arrangements, understandings or relationships (legal or otherwise) among the persons named in Item 2 hereof and between such persons and any person with respect to any securities of the Issuer, including any class of the Issuer’s securities used as a reference security, in connection with any of the following: call options, put options, security-based swaps or any other derivative securities, transfer or voting of any of the securities, finder’s fees, joint ventures, loan or option arrangements, guarantees of profits, division of profits or loss, or the giving or withholding of proxies.

     

     

    Item 7. MATERIAL TO BE FILED AS EXHIBITS
       
      None.
     
     

     

    SIGNATURES

    After reasonable inquiry and to the best of its knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Date: July 9, 2024

     

      CEVIAN CAPITAL II GP LIMITED
       
      By: /s/ Norma O’Sullivan
      Name: Norma O’Sullivan
      Title: Director

     

     

     

     

     

     
     

     

    Schedule A

     

    GENERAL PARTNERS, CONTROL PERSONS, DIRECTORS AND EXECUTIVE OFFICERS OF THE REPORTING PERSON

     

    The following sets forth the name, position, address, principal occupation and citizenship of each general partner, control person, director and/or executive officer of the Reporting Person (the “Instruction C Persons”). To the best of the Reporting Person’s knowledge, (i) none of the Instruction C Persons during the last five years has been convicted in a criminal proceeding (excluding traffic violations or other similar misdemeanors) or been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws and (ii) none of the Instruction C Persons owns any Ordinary Shares or is party to any contract or agreement as would require disclosure in this Schedule 13D.

     

    CEVIAN CAPITAL II GP LIMITED

     

    Name   Position   Citizenship   Present Principal
    Occupation
      Business Address
    Denzil Boschat   Director   Jersey   Cevian Jersey Managing Director  

    Capital House 

    8 Church Street
    St. Helier, Jersey JE2 3NN

    Ronald M. Cacciola   Director   USA   Sole Proprietor, Snowden Management LLC   252 Snowden Lane, Princeton, New Jersey, 08450-3650, USA
    W. Dexter Paine, III   Director   USA   Partner – Paine Schwartz Partners LLC  

    610 Broadway, 3rd Floor,

    New York, NY 10012, USA 

    James Bryant   Director   Jersey   Director – Highvern Fund Administrators Limited  

     

    Whiteley Chambers

    Don Street

    St. Helier, Jersey JE2 4TR

    Norma O’Sullivan   Director   Jersey   Cevian Jersey Managing Director and Managing Director of TMGA Wealth Management Limited  

    Cevian Jersey: Capital House

    8 Church Street

    St. Helier, Jersey JE2 3NN; 

    TMGA: 1st floor IFC5

    The Esplanade

    St Helier, Jersey JE2 3BY 

     

       

     
     

    Schedule B

     

    This Schedule sets forth information with respect to each purchase and sale of Ordinary Shares which were effectuated by the Reporting Person for the benefit of the Master Fund within the past sixty days. Unless otherwise noted, such transactions were effectuated in the open market through a broker.

     

     

    Trade Date Ordinary Shares Purchased (Sold) Price ($)*
    2024-06-27 1,557,020 12.46
    2024-06-28 41,324,519** 12.57
    2024-06-28 342,980 12.52
    2024-07-01 400,000 12.52
    2024-07-02 277,008 12.38
    2024-07-03 764,736 12.59

     

    *       Excluding commissions, SEC fees, etc. (rounded to nearest cent). The Ordinary Shares were purchased using British Pounds. For purposes of this Schedule 13D, a conversion rate of USD $1.27615 for each GBP 1.00 was used.

     

    **       Effected through a private transaction with a broker dealer counterparty.

     

     

    Get the next $SNN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SNN

    DatePrice TargetRatingAnalyst
    4/25/2025Buy → Hold
    HSBC Securities
    3/12/2025Buy → Neutral
    UBS
    11/6/2024Buy → Hold
    Berenberg
    11/1/2024Buy → Hold
    Deutsche Bank
    7/24/2024Buy
    Deutsche Bank
    6/5/2024Neutral → Buy
    UBS
    11/28/2023Underweight → Equal Weight
    Barclays
    11/3/2023Neutral → Overweight
    JP Morgan
    More analyst ratings

    $SNN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • A comparative sNPWT study of 10,000+ C-sections shows PICO™ sNPWT reduces complications and cuts healthcare costs by $728,000 per 1,000 patients

      Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, today announces findings from a newly published comparative study of single-use Negative Pressure Wound Therapy (sNPWT) devices in Caesarean section (C-section) recovery has identified significant benefits for postpartum use of Smith+Nephew's leading PICO sNPWT technology. Analyzing real-world data from over 10,000 C-section patients treated at different pressure levels, the study published in WOUNDS (April 2025) reveals that PICO sNPWT contributes to a significant reduction in surgical site complications (SSCs), including a reduction in the incidence of surgical site infections (SSIs), wound dehiscence and seroma, and

      5/14/25 8:00:00 AM ET
      $SNN
      Industrial Specialties
      Health Care
    • Study shows patients treated with Smith+Nephew's CARTIHEAL™ AGILI-C™ Cartilage Repair Implant have an 87% lower relative risk of Total Knee Arthroplasty or Osteotomy at 4 years¹*

      The CARTIHEAL Implant will be featured at the Arthroscopy Association of North America Annual Meeting (AANA 2025) this week Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, today announces encouraging results for its CARTIHEAL AGILI-C Cartilage Repair Implant from a recent multicentre randomised controlled trial (RCT) treating knee cartilage defects. When compared to the current surgical standard of care,* the implant demonstrated:  Superior pain relief: Patients treated with the CARTIHEAL AGILI-C Implant reported significantly better knee pain relief, and quality of life improvements over a 4-year period.1-3 **  Superior functional gains: Patients treated with the

      5/7/25 8:00:00 AM ET
      $SNN
      Industrial Specialties
      Health Care
    • Nuo Therapeutics Announces Exclusive Private Label Distribution Agreement with Smith+Nephew

      HOUSTON, April 29, 2025 (GLOBE NEWSWIRE) -- Nuo Therapeutics, Inc. (OTCQB:AURX) ("Nuo"), a commercial stage medical device company pioneering leading-edge biodynamic therapies by focusing on emerging opportunities in the evolving healthcare landscape, announced it has entered into an exclusive private label distribution agreement ("Agreement") with global medical technology company Smith+Nephew ((LSE:SN, NYSE:SNN). Under the Agreement, Smith+Nephew will market and sell CENTRIO Platelet-Rich Plasma System, their own branded version of Nuo's underlying Aurix® System to the United States wound care market. Nuo will continue to be responsible for manufacturing the product.   The Aurix product

      4/29/25 4:30:00 PM ET
      $SNN
      Industrial Specialties
      Health Care

    $SNN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Smith & Nephew downgraded by HSBC Securities

      HSBC Securities downgraded Smith & Nephew from Buy to Hold

      4/25/25 8:30:48 AM ET
      $SNN
      Industrial Specialties
      Health Care
    • Smith & Nephew downgraded by UBS

      UBS downgraded Smith & Nephew from Buy to Neutral

      3/12/25 7:34:02 AM ET
      $SNN
      Industrial Specialties
      Health Care
    • Smith & Nephew downgraded by Berenberg

      Berenberg downgraded Smith & Nephew from Buy to Hold

      11/6/24 6:23:06 AM ET
      $SNN
      Industrial Specialties
      Health Care

    $SNN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3: Plc Nephew & Smith claimed ownership of 5,428,680 units of Class A Common Stock and claimed ownership of 16,534,814 units of Class B Common Stock

      3 - SMITH & NEPHEW PLC (0000845982) (Reporting)

      2/12/21 6:00:30 AM ET
      $SNN
      Industrial Specialties
      Health Care

    $SNN
    SEC Filings

    See more
    • SEC Form 6-K filed by Smith & Nephew SNATS Inc.

      6-K - SMITH & NEPHEW PLC (0000845982) (Filer)

      5/21/25 10:40:08 AM ET
      $SNN
      Industrial Specialties
      Health Care
    • SEC Form 6-K filed by Smith & Nephew SNATS Inc.

      6-K - SMITH & NEPHEW PLC (0000845982) (Filer)

      5/14/25 8:13:22 AM ET
      $SNN
      Industrial Specialties
      Health Care
    • SEC Form SD filed by Smith & Nephew SNATS Inc.

      SD - SMITH & NEPHEW PLC (0000845982) (Filer)

      5/9/25 11:07:04 AM ET
      $SNN
      Industrial Specialties
      Health Care

    $SNN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Smith & Nephew SNATS Inc.

      SC 13D - SMITH & NEPHEW PLC (0000845982) (Subject)

      7/9/24 12:00:10 PM ET
      $SNN
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - SMITH & NEPHEW PLC (0000845982) (Subject)

      2/3/21 1:13:21 PM ET
      $SNN
      Industrial Specialties
      Health Care

    $SNN
    Leadership Updates

    Live Leadership Updates

    See more

    $SNN
    Financials

    Live finance-specific insights

    See more
    • Cadence Welcomes Bob White to Board of Directors

      STAUNTON, Va., Sept. 12, 2024 /PRNewswire/ -- Cadence, Inc., a leading provider of vertically integrated contract manufacturing solutions to the MedTech and Pharma markets, is pleased to announce the appointment of Bob White to its Board of Directors.  Mr. White brings over 25 years of business leadership experience and a proven track record in operational excellence, technological innovation, and strategic growth to Cadence. Mr. White has demonstrated exceptional skills in managing global locations, having held senior positions at Medtronic, GE Healthcare, and IBM.  He recent

      9/12/24 10:57:00 AM ET
      $SNN
      Industrial Specialties
      Health Care
    • Wound Care Market Size is Expected to Reach USD 32.75 Billion by 2033, Growing at a CAGR of 3.94%: Straits Research

      New York, United States, March 03, 2025 (GLOBE NEWSWIRE) -- The global demand for wound care products is increasing as the number of patients with chronic and acute wounds rises. Market leaders continually focus on introducing innovative wound care products to meet unmet demand. As a result, more people are using conventional, bioactive, and other wound care products. In addition, governments in developing nations and other for-profit and non-profit organizations are increasingly focusing on various awareness campaigns to educate the public about innovative product offerings and therapeutic options for chronic and advanced wounds. Download Free Sample Report PDF @ https://straitsresearc

      3/3/25 8:20:00 AM ET
      $SNN
      Industrial Specialties
      Health Care
    • Wound Care Market Will Reach USD 31.81 Billion by 2030 on the Back of Growth in the North American Market

      New York, United States, Aug. 29, 2022 (GLOBE NEWSWIRE) -- The global demand for Wound Care products is increasing as the number of patients with chronic and acute wounds rises. Market leaders continually focus on introducing innovative wound care products to meet unmet demand. As a result, more people are using conventional, bioactive, and other wound care products. In addition, governments in developing nations and other for-profit and non-profit organizations are increasingly focusing on various awareness campaigns to educate the public about innovative product offerings and therapeutic options for chronic and advanced wounds. Get a Free Sample Copy of This Report https://stra

      8/29/22 3:20:00 PM ET
      $SNN
      Industrial Specialties
      Health Care
    • Healiva® Acquires Two Wound-healing Cell Therapy Assets From Smith+Nephew

      Adds two close-to-market innovative technologies to Healiva's® growing portfolio of end-to-end care for chronic wounds Healiva®, a patient-centric company delivering life-enhancing precision medicine for patients with chronic and acute wounds, announced today the acquisition of two innovative cell therapy assets from Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology business. The acquisition enables Healiva® to establish one of the world's broadest portfolios of affordable, personalized, end-to-end wound care consisting of enzyme technology, autologous & allogenic cell therapies, and medical devices. Financial details have not been disclosed. The first asset, EpiDex®, is an

      6/1/22 2:30:00 AM ET
      $SNN
      Industrial Specialties
      Health Care